The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

After finishing at $10.44 in the prior trading day, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $10.51, up 0.67%. In other words, the price has increased by $0.67 from its previous closing price. On the day, 0.96 million shares were traded. AMLX stock price reached its highest trading level at $10.645 during the session, while it also had its lowest trading level at $10.37.

Ratios:

Our goal is to gain a better understanding of AMLX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.72 and its Current Ratio is at 8.72. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17. On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when Mazzariello Gina sold 15,000 shares for $8.34 per share. The transaction valued at 125,046 led to the insider holds 156,969 shares of the business.

Mazzariello Gina sold 15,000 shares of AMLX for $121,102 on Aug 12 ’25. The Chief Legal Officer now owns 171,969 shares after completing the transaction at $8.07 per share. On Aug 12 ’25, another insider, GINA MAZZARIELLO, who serves as the Officer of the company, bought 30,000 shares for $7.82 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 937149376 and an Enterprise Value of 762285696. Its current Enterprise Value per Revenue stands at -3061.388 whereas that against EBITDA is -3.883.

Stock Price History:

The Beta on a monthly basis for AMLX is -0.44, which has changed by 3.0894942 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $10.55, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is 27.29%, while the 200-Day Moving Average is calculated to be 98.79%.

Shares Statistics:

The stock has traded on average 1.58M shares per day over the past 3-months and 1541330 shares per day over the last 10 days, according to various share statistics. A total of 89.16M shares are outstanding, with a floating share count of 66.52M. Insiders hold about 25.40% of the company’s shares, while institutions hold 84.74% stake in the company. Shares short for AMLX as of 1755216000 were 7433417 with a Short Ratio of 4.72, compared to 1752537600 on 7466420. Therefore, it implies a Short% of Shares Outstanding of 7433417 and a Short% of Float of 9.19.

Earnings Estimates

Amylyx Pharmaceuticals Inc (AMLX) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.32 and low estimates of -$0.51.

Analysts are recommending an EPS of between -$1.63 and -$2.02 for the fiscal current year, implying an average EPS of -$1.8. EPS for the following year is -$1.52, with 7.0 analysts recommending between -$0.81 and -$1.97.